• Legend Biotech released early Phase 1 data on LB2501, an in vivo dual-targeting CAR-T candidate for relapsed or refractory B-cell non-Hodgkin lymphoma.
• Results were presented in a late-breaking session at the European Hematology Association 2026 Congress.
• Patients at the higher dose level showed broad tumor shrinkage, with most reaching complete remission; responses were ongoing at the cutoff.
• Safety looked manageable, with no severe neurologic events or treatment-related deaths; inflammatory reactions were generally mild to moderate.
• Single-infusion dosing produced in-patient CAR-T generation without chemotherapy preconditioning, a potential step toward simpler delivery and wider access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606140315PRIMZONEFULLFEED9745917) on June 14, 2026, and is solely responsible for the information contained therein.